109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
系统性炎症综合指数低值与肝细胞癌良好预后及拟杆菌属丰度高相关
Authors Sun W, Zhou F, Shi C, Xu C, Wang Z, Guo X
Received 3 May 2025
Accepted for publication 23 October 2025
Published 6 November 2025 Volume 2025:12 Pages 2491—2500
DOI https://doi.org/10.2147/JHC.S538192
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Ahmed Kaseb
Wenju Sun,1,* Fengqin Zhou,2,* Chengyu Shi,3 Congcong Xu,4 Zhihai Wang,4 Xufeng Guo5
1Department II of Radiotherapy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People’s Republic of China; 2Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 3Hepatobiliary Surgery I, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People’s Republic of China; 4Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People’s Republic of China; 5Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhihai Wang, Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, No. 127, Siliu South Road, Sifang District, Qingdao, Shandong, 266000, People’s Republic of China, Email wangzhihai0225@126.com Xufeng Guo, Department of Oncology, Renmin Hospital of Wuhan University, No. 99 Ziyang Road, Wuhan, Hubei, 430000, People’s Republic of China, Email guoxufeng007@126.com
Purpose: Systemic inflammatory response is reported to occupy a crucial role in the progression of hepatocellular carcinoma (HCC). The prognostic significance of SII and PNI in HCC has been explored, but the prognostic significance of aggregate index of systemic inflammation (AISI) in HCC is still unknown. This study was designed to determine the prognostic significance of AISI in HCC and explain the potential underlying mechanisms via gut microbiota and fecal metabolomic profiling.
Patients and Methods: A cohort of 109 cases of HCC individuals during January 2023 to August 2024 was included into this clinical research, and the clinical information and fresh fecal samples were collected. The fecal samples were collected for 16S rRNA sequence and metabolomics analysis.
Results: Survival analysis revealed that HCC patients in low AISI group tend to experience relatively longer survival time compared with those in high AISI group. Then, we employed ROC analysis to measure the predictive performance of AISI for the survival outcome, and ROC curve showed that levels of AISI had good predictive performance for the survival status with an AUC of 0.771 (95%CI: 0.671– 0.871). 16S rRNA sequencing results revealed that levels of Parabacteroides were up-regulated in the low AISI group, and levels of Fusicatenibacter were up-regulated in the high AISI group. Metabolic analysis demonstrated that cavipetin A, pemptoporphyrin, and 8-Oxo-dGMP with high VIP value were the most distinct fecal metabolites.
Conclusion: AISI is a potential prognostic biomarker in individuals with HCC. A low level of AISI was correlated with high abundance of Parabacteroides and some metabolites, indicating that AISI might affect the prognosis of HCC individuals via the regulations of gut microbes and metabolites.
Keywords: hepatocellular carcinoma, gut microbes, parabacteroides, aggregate index of systemic inflammation, metabolites
1Department II of Radiotherapy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People’s Republic of China; 2Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 3Hepatobiliary Surgery I, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People’s Republic of China; 4Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People’s Republic of China; 5Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhihai Wang, Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, No. 127, Siliu South Road, Sifang District, Qingdao, Shandong, 266000, People’s Republic of China, Email wangzhihai0225@126.com Xufeng Guo, Department of Oncology, Renmin Hospital of Wuhan University, No. 99 Ziyang Road, Wuhan, Hubei, 430000, People’s Republic of China, Email guoxufeng007@126.com
Purpose: Systemic inflammatory response is reported to occupy a crucial role in the progression of hepatocellular carcinoma (HCC). The prognostic significance of SII and PNI in HCC has been explored, but the prognostic significance of aggregate index of systemic inflammation (AISI) in HCC is still unknown. This study was designed to determine the prognostic significance of AISI in HCC and explain the potential underlying mechanisms via gut microbiota and fecal metabolomic profiling.
Patients and Methods: A cohort of 109 cases of HCC individuals during January 2023 to August 2024 was included into this clinical research, and the clinical information and fresh fecal samples were collected. The fecal samples were collected for 16S rRNA sequence and metabolomics analysis.
Results: Survival analysis revealed that HCC patients in low AISI group tend to experience relatively longer survival time compared with those in high AISI group. Then, we employed ROC analysis to measure the predictive performance of AISI for the survival outcome, and ROC curve showed that levels of AISI had good predictive performance for the survival status with an AUC of 0.771 (95%CI: 0.671– 0.871). 16S rRNA sequencing results revealed that levels of Parabacteroides were up-regulated in the low AISI group, and levels of Fusicatenibacter were up-regulated in the high AISI group. Metabolic analysis demonstrated that cavipetin A, pemptoporphyrin, and 8-Oxo-dGMP with high VIP value were the most distinct fecal metabolites.
Conclusion: AISI is a potential prognostic biomarker in individuals with HCC. A low level of AISI was correlated with high abundance of Parabacteroides and some metabolites, indicating that AISI might affect the prognosis of HCC individuals via the regulations of gut microbes and metabolites.
Keywords: hepatocellular carcinoma, gut microbes, parabacteroides, aggregate index of systemic inflammation, metabolites